Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?--Results from the lung cancer economics and outcomes research (LUCEOR) study.
Lester JF, Agulnik J, Akerborg O, Chouaid C, De Geer A, Finnern HW, Herder GJ, Lungershausen J, Mitchell PL, Vansteenkiste J, Ziske C, Goker E. Lester JF, et al. Among authors: agulnik j. Lung Cancer. 2013 Oct;82(1):128-35. doi: 10.1016/j.lungcan.2013.06.023. Epub 2013 Jul 31. Lung Cancer. 2013. PMID: 23910909
Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting.
Chouaid C, Agulnik J, Goker E, Herder GJ, Lester JF, Vansteenkiste J, Finnern HW, Lungershausen J, Eriksson J, Kim K, Mitchell PL. Chouaid C, et al. Among authors: agulnik j. J Thorac Oncol. 2013 Aug;8(8):997-1003. doi: 10.1097/JTO.0b013e318299243b. J Thorac Oncol. 2013. PMID: 23787802 Free article.
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn MJ, Tiangco B, Voccia I, Pawel JV, Kovcin V, Agulnik J, Gaschler-Markefski B, Barrueco J, Sikken P, Schloss C, Kim JH; LUME-Lung 2 Study group. Hanna NH, et al. Among authors: agulnik j. Lung Cancer. 2016 Dec;102:65-73. doi: 10.1016/j.lungcan.2016.10.011. Epub 2016 Oct 27. Lung Cancer. 2016. PMID: 27987591 Clinical Trial.
Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.
Barghout SH, Zhan LJ, Raptis S, Al-Agha F, Esfahanian N, Popovacki A, Kasymjanova G, Proulx-Rocray F, Chan SWS, Richardson M, Brown MC, Patel D, Dean ML, Navani V, Moore E, Carvery L, Yan E, Goldshtein D, Cleary-Gosine J, Gibson AJ, Hubley L, Balaratnam K, Ngo T, Gill A, Black M, Sacher A, Bradbury PA, Shepherd FA, Leighl N, Cheema P, Kuruvilla S, Agulnik J, Banerji S, Juergens R, Blais N, Cheung W, Wheatley-Price P, Liu G, Snow S. Barghout SH, et al. Among authors: agulnik j. Lung Cancer. 2024 Aug;194:107898. doi: 10.1016/j.lungcan.2024.107898. Epub 2024 Jul 25. Lung Cancer. 2024. PMID: 39074423
45 results